Literature DB >> 19504273

Emergence of extensive-drug-resistant Pseudomonas aeruginosa in a French university hospital.

L Vettoretti1, N Floret, D Hocquet, B Dehecq, P Plésiat, D Talon, X Bertrand.   

Abstract

The aim of this study was to describe the molecular epidemiology and the mechanisms of resistance to beta-lactams of emerging extensive-drug-resistant Pseudomonas aeruginosa (XDRPA) in a tertiary-care university hospital over a three-year period. Analysis included antimicrobial susceptibility profiling and pulsed-field gel electrophoresis (PFGE). Resistance mechanisms to beta-lactams were identified: production of naturally occurring and acquired beta-lactamases, overproduction of MexAB-OprM and MexXY efflux systems and loss of porin OprD were assessed. Eighteen patients were colonised or infected with XDRPA which remained susceptible to colistin and, to a lesser extent, to rifampicin. beta-lactam resistance was, in most cases, due to the overproduction of AmpC, overproduction of the MexXY efflux system and loss of porin OprD. One isolate produced the class D extended-spectrum oxacillinase (OXA-ESBL) Oxa-28, but none produced metallo-beta-lactamase (MBL) or class A extended-spectrum beta-lactamase (ESBL). The XDRPA clustered in eight PFGE patterns and both the acquisition and loss of resistance determinants was observed within a single clone during its spread. The emergence of XDRPA isolates in our university hospital has been characterised by genotypic heterogeneity, variation of mechanisms of resistance to beta-lactams in a single clone and the predominance of chromosomally encoded resistance mechanisms.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19504273     DOI: 10.1007/s10096-009-0767-8

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  23 in total

1.  Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of Pseudomonas aeruginosa clinical isolates.

Authors:  John Quale; Simona Bratu; Jyoti Gupta; David Landman
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

2.  Susceptibility to beta-lactam antibiotics of Pseudomonas aeruginosa overproducing penicillin-binding protein 3.

Authors:  X Liao; R E Hancock
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

3.  Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa.

Authors:  Didier Hocquet; Patrice Nordmann; Farid El Garch; Ludovic Cabanne; Patrick Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

Review 4.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing.

Authors:  F C Tenover; R D Arbeit; R V Goering; P A Mickelsen; B E Murray; D H Persing; B Swaminathan
Journal:  J Clin Microbiol       Date:  1995-09       Impact factor: 5.948

5.  Endemicity, molecular diversity and colonisation routes of Pseudomonas aeruginosa in intensive care units.

Authors:  X Bertrand; M Thouverez; D Talon; A Boillot; G Capellier; C Floriot; J P Hélias
Journal:  Intensive Care Med       Date:  2001-08       Impact factor: 17.440

6.  Analysis of antibiotic resistance gene expression in Pseudomonas aeruginosa by quantitative real-time-PCR.

Authors:  Jean-Luc Dumas; Christian van Delden; Karl Perron; Thilo Köhler
Journal:  FEMS Microbiol Lett       Date:  2006-01       Impact factor: 2.742

7.  Substrate specificities of MexAB-OprM, MexCD-OprJ, and MexXY-oprM efflux pumps in Pseudomonas aeruginosa.

Authors:  N Masuda; E Sakagawa; S Ohya; N Gotoh; H Tsujimoto; T Nishino
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

8.  Molecular characterization of an epidemic clone of panantibiotic-resistant Pseudomonas aeruginosa.

Authors:  A Deplano; O Denis; L Poirel; D Hocquet; C Nonhoff; B Byl; P Nordmann; J L Vincent; M J Struelens
Journal:  J Clin Microbiol       Date:  2005-03       Impact factor: 5.948

9.  Role of the multidrug efflux system MexXY in the emergence of moderate resistance to aminoglycosides among Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  Christelle Vogne; Julio Ramos Aires; Christiane Bailly; Didier Hocquet; Patrick Plésiat
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

10.  Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study.

Authors:  H Kallel; L Hergafi; M Bahloul; A Hakim; H Dammak; H Chelly; C Ben Hamida; A Chaari; N Rekik; M Bouaziz
Journal:  Intensive Care Med       Date:  2007-05-25       Impact factor: 17.440

View more
  12 in total

Review 1.  Broad-specificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria.

Authors:  Hiroshi Nikaido; Jean-Marie Pagès
Journal:  FEMS Microbiol Rev       Date:  2011-07-29       Impact factor: 16.408

2.  Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.

Authors:  Didier Hocquet; Patrick Plésiat; Barbara Dehecq; Pierre Mariotte; Daniel Talon; Xavier Bertrand
Journal:  Antimicrob Agents Chemother       Date:  2010-06-14       Impact factor: 5.191

3.  Oxidative stress induction of the MexXY multidrug efflux genes and promotion of aminoglycoside resistance development in Pseudomonas aeruginosa.

Authors:  Sebastien Fraud; Keith Poole
Journal:  Antimicrob Agents Chemother       Date:  2010-12-20       Impact factor: 5.191

4.  Most multidrug-resistant Pseudomonas aeruginosa isolates from hospitals in eastern France belong to a few clonal types.

Authors:  Pascal Cholley; Michelle Thouverez; Didier Hocquet; Nathalie van der Mee-Marquet; Daniel Talon; Xavier Bertrand
Journal:  J Clin Microbiol       Date:  2011-05-18       Impact factor: 5.948

5.  The prophylactic effects of human IgG derived from sera containing high anti-PcrV titers against pneumonia-causing Pseudomonas aeruginosa.

Authors:  Mao Kinoshita; Hideya Kato; Hiroaki Yasumoto; Masaru Shimizu; Saeko Hamaoka; Yoshifumi Naito; Koichi Akiyama; Kiyoshi Moriyama; Teiji Sawa
Journal:  Hum Vaccin Immunother       Date:  2016-07-25       Impact factor: 3.452

6.  Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients.

Authors:  Laurence Armand-Lefèvre; Cécile Angebault; François Barbier; Emilie Hamelet; Gilles Defrance; Etienne Ruppé; Régis Bronchard; Raphaël Lepeule; Jean-Christophe Lucet; Assiya El Mniai; Michel Wolff; Philippe Montravers; Patrick Plésiat; Antoine Andremont
Journal:  Antimicrob Agents Chemother       Date:  2013-01-14       Impact factor: 5.191

7.  MexXY multidrug efflux system of Pseudomonas aeruginosa.

Authors:  Yuji Morita; Junko Tomida; Yoshiaki Kawamura
Journal:  Front Microbiol       Date:  2012-11-28       Impact factor: 5.640

8.  Pseudomonas aeruginosa: resistance to the max.

Authors:  Keith Poole
Journal:  Front Microbiol       Date:  2011-04-05       Impact factor: 5.640

9.  Risk factors and the resistance mechanisms involved in Pseudomonas aeruginosa mutation in critically ill patients.

Authors:  Stéphanie Druge; Stéphanie Ruiz; Fanny Vardon-Bounes; Marion Grare; François Labaste; Thierry Seguin; Olivier Fourcade; Vincent Minville; Jean-Marie Conil; Bernard Georges
Journal:  J Intensive Care       Date:  2019-07-19

10.  Tracking down antibiotic-resistant Pseudomonas aeruginosa isolates in a wastewater network.

Authors:  Céline Slekovec; Julie Plantin; Pascal Cholley; Michelle Thouverez; Daniel Talon; Xavier Bertrand; Didier Hocquet
Journal:  PLoS One       Date:  2012-12-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.